KingMed Diagnostics and Illumina Forge New Strategic Collaboration to Advance Precision Oncology in China

ShanghaiJuly 28, 2022PR Newswire -- On July 27, Illumina and KingMed Diagnostics announced a new strategic partnership for tumor genetic testing. Both parties will fully leverage their respective strengths to promote the development of NGS technology in the precise management of tumors across the entire disease process, and jointly work towards making precision medicine testing solutions more accessible to patients in China.

KingMed Diagnostics Chairman and CEO Yaoming Liang stated, "As a leader in the third-party medical testing industry, KingMed Diagnostics possesses a comprehensive technology platform, a service network covering all of China, and strong operational capabilities, committed to providing high-quality, affordable, and accessible medical testing services for clinicians and patients. In the future, KingMed will work together with Illumina to leverage each other's strengths and provide patients with higher quality, cost-effective, and standardized tumor genetic testing."

Illumina's Global Senior Vice President and General Manager for Greater China, Li Qing, stated: "Since entering the Chinese market, Illumina has consistently adhered to a localized strategy of 'In China, For China,' collaborating with Chinese partners to develop localized precision medicine innovation testing solutions that meet the needs of Chinese patients. KingMed Diagnostics is a leading company in China’s medical testing industry, and we are delighted to elevate our partnership to another new stage. I believe that through our joint efforts, more Chinese cancer patients will gain access to high-quality precision medicine testing products."